Lymphomas and acute abdomen – a set of case reports

Download PDF Česká verze

Authors: V. Čan ¹; P. Moravčík ¹; A. Janíková ²; Z. Kala ¹; J. Pánek ³; I. Penka ¹
Authors place of work: Chirurgická klinika Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity v Brně ¹; Interní hematologická a onkologická klinika Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity v Brně ²; Klinika radiologie a nukleární medicíny Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity v Brně ³
Published in the journal: Rozhl. Chir., 2019, roč. 98, č. 8, s. 328-334.
Category: Kazuistika
doi: https://doi.org/10.33699/PIS.2019.98.8.328–334

Summary

Surgical treatment of gastrointestinal solid tumors is the basic method with a curative potential. However, the first-line treatment modalities in lymphomas are systemic oncology therapy (chemotherapy, immunotherapy and hematopoietic stem cell transplantation), radiotherapy or their combination. Surgery in lymphomas is predominantly associated with acute disease and dominantly, surgery is still used mainly in diagnosing lymphomas. Acute abdomen associated with lymphoma can be divided into 3 groups: bleeding, obstruction and perforation of GIT due to lymphoma. All these conditions might be caused by both gastrointestinal (extranodal) lymphomas or advanced nodal lymphomas that directly infiltrate or compress gastrointestinal tract (GIT) as well. Perforation is also often associated with the effect of systemic chemotherapy administration. When treating acute abdomen conditions caused by lymphomas, multidisciplinary cooperation with all participating experts is necessary. From the surgical point of view, minimizing the risk of postoperative complications is crucial to ensure the possibility of early systemic oncological treatment administration.

Keywords:

bleeding – lymphoma – acute abdomen – GIT obstruction – intestine perforation

Zdroje

Ústav zdravotních informací a statistiky: Novotvary 2015 ČR, Cancer incidence in the Czech Republic. ISSN 1210-857X, (0862-576X, 0862-5778), available from: http://www.uzis.cz/katalog/zdravotnicka-statistika/novotvary.
Libson E, Mapp E, Dachman AH. Hodgkin’s disease of the gastrointestinal tract. Clin Radiol. 1994;49:166−9.
Janíková A, Zambo I, Baumeisterová A, et al. Lymfomy gastrointestinálního traktu – klinicko-patologický přehled. Transfuze Hematol 2013;3:140−51.
Howell JM, Auer-Grzesiak I, Zhang J, et al. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can J Gastroenterol. 2012;26:452−6.
Song LN, Cen XN, Ou JP, et al. Clinical and prognostic analysis of 101 cases of primary gastrointestinal Non-Hodgkin´s lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013;21:387−91.
Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004;350:239−48. doi:10.1056/NEJMoa031887
Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005;105:2274−80. doi:10.1182/blood-2004-07-2755
Schechter NR, Yahalom J. Low-grade MAL T lymphoma of the stomach: A review of treatment options. Int J Rad Oncol Biol Phys. 2000;46:1093−1103.
Dreyling M, Thieblemont C, Gallamini A, et al. ESMO consensus conference: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857−77.
Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study J Clin Oncol. 2013;10:31:565−72. doi: 10.1200/JCO.2011.40.6272.
Zucca E, Gregorini A, Cavalli F. Management of non-Hodgkin lymphomas arising at extranodal sites. Therapeutische Umschau. 2010;67. doi: 10.1024/0040-5930/a000088.
Gobbi PG, Ghirardelli ML, Cavalli C, et al. The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas. Haematologica 2000;85:372−80.
Matyasik-Budnik T, Fabiani B, Hennequin C, et al. Gastrointestinal lymphomas: French intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). Dig Liver Dis. 2018;50:124−31. doi: 10.1016/j.dld.2017.12.006.
Hussell T, Isaacson PG, Crabtree JE, et al. Helicobacter pylori-specific tumour infiltrating cells provide contact dependent help for growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol. 1996;178:122−7. doi:10.1002/(SICI)1096-9896(199602)178:2<122:AID-PATH486>3.0.CO;2-D
Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H.pylori-positive gastric diffuse large B-cell lymphomas. Blood 2012;119:4838−44. doi: 10.1182/blood-2012-01-404194.
Stolte M, Bayerdörffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut 2002;50:19−24. doi: 10.1136/gut.50.suppl_3.iii19.
Spectre G, Libster D, Grisariu S, et al. Bleeding, obstruction, and perforation in a series of patients with aggressive gastric lymphoma treated with primary chemotherapy. Ann Surg Oncol. 2006;13:1372−8. doi:10.1245/s10434-006-9069-x
Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24:561−76. doi: 10.1093/annonc/mds517.
Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697−707. doi: 10.3748/wjg.v17.i6.697.
Sojka L, Makajevova V, Simka J, et al. Primární lymfomy zažívacího traktu z pohledu chirurga. Rozhl Chir. 2017;96:276−83.
Hlaváčová L, Vrba R, Gregořík M, et al. Multiorgánová chirurgická resekce pro rozsáhlý lymfom dutiny břišní. Rozhl Chir. 2017;96:37−40.
Shakya VC, Agrawal CS, Koirala R, et al. Intussusception due to non Hodgkin’s lymphoma; different experiences in two children: two case reports. Cases J. 2009;2:6304. doi: 10.4076/1757-1626-2-6304.
Vaidya R1, Habermann TM, Donohue JH, et al. Bowel perforation in intestinal lymphoma: incidence and clinical features, Ann Onc. 2013;24:2439–43. doi: 10.1093/annonc/mdt188.
Hsiao CH, Lee WI, Chang SL, et al. Angiocentric T-cell lymphoma of the intestine: A distinct etiology of ischemic bowel disease. Gastroenterol. 1996;110:985−90.
Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857–64.
Hoch J, Kubáčková K. Lymfom rekta – diagnóza k operaci? Rozhl Chir. 2009;88:317−9.